Positive Atopic Dermatitis Data On Lilly's Newly-Approved Olumiant

Just Received European Green Light For Skin Disorder

It has gone under the radar that Eli Lilly and Incyte's Olumiant has recently become the first JAK inhibitor to be approved anywhere for atopic dermatitis and the companies have been touting promising long-term data on the therapy as it expands beyond rheumatoid arthritis.  

Scratching
Atopic dermatitis is a potentially lucrative market for Lilly • Source: Shutterstock

Days after Olumiant became the first JAK inhibitor to be approved in Europe for atopic dermatitis,Eli Lilly and Company and partner Incyte Corporation have presented more positive data on the drug for the skin disease and highlighted its potential as a treatment for alopecia.

The US giant gave little fanfare to the European Commission's approval last week for Olumiant (baricitinib) for the treatment of...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip